Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.
Forest Laboratories (FRX) Breaks Through Resistance at $99.51
Comtex SmarTrend(R) - Tue Jun 24, 10:12AM CDT
Forest Laboratories (NYSE:FRX) has opened bullishly above the pivot of $98.69 today and has reached the first level of resistance at $99.51. Investors may be interested in a cross of the next upside pivot targets of $100.28 and $101.87.
Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline"
Forest Laboratories, Inc. Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
Business Wire - Mon Jun 23, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients who received vilazodone demonstrated statistically significant improvement from baseline in the Hamilton Rating Scale for Anxiety (HAM-A) total score versus placebo at week 8, the primary endpoint.
3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Trade-Ideas: Forest Laboratories (FRX) Is Today's Momo Momentum Stock
at The Street - Mon Jun 23, 9:01AM CDT
Trade-Ideas LLC identified Forest Laboratories (FRX) as a momo momentum candidate
Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -
Forest Laboratories, Inc. to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
Business Wire - Fri Jun 20, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that data on the investigational drug cariprazine will be presented at the International College of Neuropsychopharmacology (CINP) 29th World Congress, scheduled June 22-26, 2014 in Vancouver, Canada.
Research and Markets: Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
Business Wire - Fri Jun 20, 10:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vvmps/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Fri Jun 20, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d7b94m/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cariprazine for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 5 Competitive Assessment 6 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 7 Pipeline Assessment 8 Cariprazine (RGH-188) 9 Appendix For more information visit http://www.researchandmarkets.com/research/d7...ariprazine
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
Will Forest Laboratories (FRX) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 7:50AM CDT
Recent estimates have been moving higher for Forest Laboratories.
Forest Laboratories acquires extended US market pediatric exclusivity for NAMENDA and NAMENDA XR by six months
M2 - Thu Jun 19, 4:56AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Wednesday that it has received the US Food and Drug Administration's (FDA) pediatric exclusivity for memantine hydrochloride.
Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...
Next Resistance Level for Forest Laboratories (FRX) is $99.30
Comtex SmarTrend(R) - Wed Jun 18, 9:02AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $96.19 today and have reached the first resistance level of $97.94. Analysts will be watching for a cross of the next upside pivot targets of $99.30 and $102.41.